TALEN

TALEN1-rangrf

ID
ZDB-TALEN-211028-1
Name
TALEN1-rangrf
Previous Names
None
Target
Target Sequence 1
5' - CTCAAACAGACCAGAGTAT - 3'
ZFIN BLAST NCBI BLAST Ensembl
Target Sequence 2
5' - GCACTTGGCTTTGATACT - 3'
ZFIN BLAST NCBI BLAST Ensembl
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
hzu101 rangrf
hzu102 rangrf
Expression
Gene expression in Wild Types + TALEN1-rangrf
No data available
Phenotype
Phenotype resulting from TALEN1-rangrf
No data available
Phenotype of all Fish created by or utilizing TALEN1-rangrf
Phenotype Fish Conditions Figures
heart dlg1a expression increased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 6 from Gou et al., 2020
heart heart looping process quality, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
heart rangrf expression decreased amount, abnormal rangrfhzu101/hzu101 (AB) chemical treatment by environment: isoprenaline Fig. 4 from Gou et al., 2020
anterior lateral plate mesoderm nkx2.5 expression decreased distribution, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
heart cryabb expression decreased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 3,  Fig. 4 from Gou et al., 2020
heart nppa expression increased amount, abnormal rangrfhzu101/hzu101 (AB) chemical treatment by environment: isoprenaline Fig. 4 from Gou et al., 2020
whole organism rangrf expression decreased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 1 from Gou et al., 2020
heart calm3a expression increased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 6 from Gou et al., 2020
heart scn1ba expression decreased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 6 from Gou et al., 2020
atrioventricular canal endocardium notch1b expression decreased distribution, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
cardiac ventricle myh7 expression spatial pattern, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
atrioventricular canal myocardium vcana expression decreased distribution, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
heart heart contraction decreased process quality, abnormal rangrfhzu101/hzu101 (AB) chemical treatment by environment: isoprenaline Fig. 4 from Gou et al., 2020
heart heart contraction decreased rate, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 6 from Gou et al., 2020
heart heart contraction decreased process quality, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 2,  Fig. 6 from Gou et al., 2020
heart hspb2 expression decreased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 3,  Fig. 4 from Gou et al., 2020
pericardium edematous, exacerbated rangrfhzu101/hzu101 (AB) chemical treatment by environment: isoprenaline Fig. 4 from Gou et al., 2020
heart myl7 expression spatial pattern, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
heart ank3a expression increased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 6 from Gou et al., 2020
heart cryabb expression decreased amount, abnormal rangrfhzu101/hzu101 (AB) chemical treatment by environment: isoprenaline Fig. 4 from Gou et al., 2020
heart rangrf expression decreased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 1,  Fig. 4 from Gou et al., 2020
heart nppa expression increased distribution, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 2 from Gou et al., 2020
heart nppa expression increased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 4 from Gou et al., 2020
heart nppb expression increased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 4 from Gou et al., 2020
pericardium edematous, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 2 from Gou et al., 2020
anterior lateral plate mesoderm gata4 expression decreased distribution, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
heart nppb expression increased amount, abnormal rangrfhzu101/hzu101 (AB) chemical treatment by environment: isoprenaline Fig. 4 from Gou et al., 2020
ventricular myocardium increased thickness, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 2 from Gou et al., 2020
ventricular myocardium increased thickness, abnormal rangrfhzu101/hzu101 (AB) chemical treatment by environment: isoprenaline Fig. 4 from Gou et al., 2020
heart hspb2 expression decreased amount, abnormal rangrfhzu101/hzu101 (AB) chemical treatment by environment: isoprenaline Fig. 4 from Gou et al., 2020
anterior lateral plate mesoderm hand2 expression decreased distribution, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
atrioventricular canal endocardium has2 expression decreased distribution, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
whole organism decreased weight, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 2 from Gou et al., 2020
heart actn2a expression increased amount, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 6 from Gou et al., 2020
atrium myh6 expression spatial pattern, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
atrioventricular canal myocardium bmp4 expression decreased distribution, abnormal rangrfhzu101/hzu101 (AB) standard conditions Fig. 7 from Gou et al., 2020
heart heart looping process quality, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
anterior lateral plate mesoderm nkx2.5 expression decreased distribution, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
whole organism rangrf expression decreased amount, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 1 from Gou et al., 2020
atrioventricular canal endocardium notch1b expression decreased distribution, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
heart heart contraction decreased process quality, abnormal rangrfhzu102/hzu102 (AB) chemical treatment by environment: isoprenaline Fig. 4 from Gou et al., 2020
cardiac ventricle myh7 expression spatial pattern, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
atrioventricular canal myocardium vcana expression decreased distribution, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
heart heart contraction decreased rate, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 6 from Gou et al., 2020
heart heart contraction decreased process quality, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 2,  Fig. 6 from Gou et al., 2020
heart myl7 expression spatial pattern, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
heart nppa expression increased distribution, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 2 from Gou et al., 2020
heart rangrf expression decreased amount, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 1 from Gou et al., 2020
ventricular myocardium increased thickness, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 2 from Gou et al., 2020
anterior lateral plate mesoderm gata4 expression decreased distribution, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
anterior lateral plate mesoderm hand2 expression decreased distribution, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
whole organism decreased weight, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 2 from Gou et al., 2020
atrium myh6 expression spatial pattern, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
atrioventricular canal myocardium bmp4 expression decreased distribution, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
atrioventricular canal endocardium has2 expression decreased distribution, abnormal rangrfhzu102/hzu102 (AB) standard conditions Fig. 7 from Gou et al., 2020
heart heart looping process quality, abnormal rangrfhzu101/hzu101; twu34Tg (AB) standard conditions Fig. S4 from Gou et al., 2020
heart EGFP expression spatial pattern, abnormal rangrfhzu101/hzu101; twu34Tg (AB) standard conditions Fig. S4 from Gou et al., 2020
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.